Hop til indhold
- Skougaard K, Østrup O et.al: Surveillance with PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion ofDefinitive Therapy: A Randomized Controlles Trial (SUPER) Clinical Lung Cancer, 2020-0301 Volume 21, Issue 2: e61-e64.
- Frank M, Bødtger U et. al: Re-biopsy after first line treatment in advances NSCLC can reveal changes in PD-L1 expression Lung Cancer, Volume 149: 23-32.
- L. Winther, Kr. Larsen, WE. Langer, M. Quist: THE 6-MINUTE WALK TEST AS A PRE-TREATMENT PREDICTOR FOR ADVERSE EVENTS IN PATIENTS WITH LUNG CANCER: A FEASIBILITY STUDY
- Malene Støchkel Frank, Uffe Bodtger, Julie Gehl and Lise Barlebo Ahlborn: Actionable Molecular Alterations are Revealed in Majority of Advanced NOn-Small Cell Lunge Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment